$7.19
0.15[2.13%]
At close: May 17
$7.19
0[0.00%]
After Hours: 7:50PM EDT
Prime Medicine
(NASDAQ:PRME)Latest News for Prime Medicine Stock (NASDAQ:PRME)
Prime Medicine Stock (NASDAQ: PRME)
Categories: All
Thursday, May 16, 2024
Monday, May 13, 2024
Friday, May 10, 2024
Tuesday, May 07, 2024
Thursday, May 02, 2024
Monday, April 29, 2024
- Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Apr 29, 2024, 1:04PM
- Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On MondayAvi Kapoor - Apr 29, 2024, 10:47AM
- Prime Medicine shares are trading higher on FDA clearance of its IND application for PM359.Benzinga Newsdesk - Apr 29, 2024, 7:14AM
- Prime Medicine Reports FDA Clearance Of Investigational New Drug Application For PM359 For Treatment Of Chronic Granulomatous DiseaseBenzinga Newsdesk - Apr 29, 2024, 7:05AM
- Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)Benzinga Newsdesk - Apr 29, 2024, 7:01AM
Friday, April 26, 2024
Tuesday, April 23, 2024
- Wedbush Reiterates Outperform on Prime Medicine, Maintains $12 Price TargetBenzinga Newsdesk - Apr 23, 2024, 1:14PM
- Prime Medicine shares are trading higher after the company announced that it will present preclinical data highlighting the broad potential of its Prime Editing technology and supporting the advancement of its programs at upcoming scientific meetings.Benzinga Newsdesk - Apr 23, 2024, 10:54AM
- Prime Medicine To Present Preclinical Data Demonstrating Broad Potential Of Prime Editing Technology At Upcoming Scientific MeetingsBenzinga Newsdesk - Apr 23, 2024, 8:18AM
Monday, April 22, 2024
Monday, April 08, 2024
Wednesday, April 03, 2024
- Prime Medicine shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and $12 price target.Benzinga Newsdesk - Apr 3, 2024, 7:49AM
- Wedbush Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $12Benzinga Newsdesk - Apr 3, 2024, 5:29AM
Tuesday, April 02, 2024
Tuesday, March 05, 2024
Friday, March 01, 2024
Thursday, February 15, 2024
Wednesday, February 14, 2024
Tuesday, January 16, 2024
Friday, January 05, 2024
- Prime Medicine and Myeloid Therapeutics Announce Settlement Of Pending Disputes, Signaling An End To The Pending Arbitrations And A Positive Outcome For Both PartiesBenzinga Newsdesk - Jan 5, 2024, 5:04PM
- Prime Medicine Appoints Allan Reine As CFO Effective Jan. 17Benzinga Newsdesk - Jan 5, 2024, 8:25AM
Friday, December 22, 2023
Friday, December 08, 2023
Tuesday, November 07, 2023
Monday, November 06, 2023
- Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day SessionLisa Levin - Nov 6, 2023, 1:36PM
- Ryanair Holdings, Prime Medicine And Other Big Stocks Moving Higher In Monday's Pre-Market SessionLisa Levin - Nov 6, 2023, 6:13AM
- DISH Network, Goodyear And 3 Stocks To Watch Heading Into MondayLisa Levin - Nov 6, 2023, 2:15AM
Friday, November 03, 2023
Tuesday, October 17, 2023
Monday, October 09, 2023
- Preclinical-Phase Firm Prime Medicine's Gene Editing Platform Has Potential: AnalystVandana Singh - Oct 9, 2023, 2:19PM
- Benzinga's Top Ratings Upgrades, Downgrades For October 9, 2023Benzinga Insights - Oct 9, 2023, 11:00AM
- Analyst Ratings for Prime MedicineBenzinga Insights - Oct 9, 2023, 8:00AM
- BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $19Benzinga Newsdesk - Oct 9, 2023, 7:09AM